History of neoadjuvant therapy for rectal cancer

Tiffany Chan, Radhika K. Smith

Research output: Contribution to journalArticle

Abstract

Management of rectal cancer has evolved extensively over the last 30 years. Treatment of locally advanced rectal cancer currently incorporates surgery, chemotherapy, and radiation. Radiation was initially utilized as a salvage method as historic surgical practices were associated with high morbidity rates. In present day, multiple studies have demonstrated that the use of radiation as an adjunct to surgery decreases local recurrence rates. The now routine practice of total mesorectal excision during rectal cancer surgery has further improved outcomes. Numerous studies have evaluated the chemotherapeutic regimens as adjuncts to radiation therapy. Currently, fluorouracil-based regimens are commonly incorporated into neoadjuvant therapy for locally advanced rectal cancer, whereas oxaliplatin has not been incorporated due to more recent studies demonstrating increased toxicity and no clear oncologic benefit. Presently, trials are underway that aim to tailor therapies to specific patterns of disease, in hopes of allowing clinicians to selectively omit components of therapy to limit toxicity and morbidity while maintaining or improving oncologic outcomes. Thus, rectal cancer treatment continues to evolve, and decision-making surround treatment remains highly individualized and nuanced.

Original languageEnglish
Pages (from-to)58-62
Number of pages5
JournalSeminars in Colon and Rectal Surgery
Volume30
Issue number2
DOIs
StatePublished - Jun 2019

Keywords

  • Locally advanced rectal cancer
  • Neoadjuvant therapy
  • Radiation

Fingerprint Dive into the research topics of 'History of neoadjuvant therapy for rectal cancer'. Together they form a unique fingerprint.

  • Cite this